https://www.live-feeds.com/feed/why-biotech-stocks-are-celebrating-this-nail-biterContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/why-biotech-stocks-are-celebrating-this-nail-biterhttps://www.live-feeds.com/feed/why-biotech-stocks-are-celebrating-this-nail-biter#u9645Tue, 23 Jun 2026 09:41:05 +0000UniQure is preparing a licensing application for its AMT-130 gene therapy. This action follows a reversal by the FDA after a prior disagreement. Biotech stocks climbed on Wednesday following this news.What's confirmed:UniQure plans to submit a licensing application to the FDA for its AMT-130 gene therapy targeting Huntington's disease.The FDA reversed a previous position following a dispute.Still unconfirmed:Biotech stocks rose Wednesday due to the UniQure development.Biotech stocks gained over 75% after hitting a low in April due to acquisitions and clinical data.The biotech sector conti https://www.live-feeds.com/feed/why-biotech-stocks-are-celebrating-this-nail-biterhttps://www.live-feeds.com/feed/why-biotech-stocks-are-celebrating-this-nail-biter#u5349Sat, 20 Jun 2026 02:01:59 +0000UniQure plans to submit a licensing application to the FDA for its AMT-130 gene therapy targeting Huntington's disease. The move follows a reversal by the agency after a previous dispute. Biotech stocks rose Wednesday as a result of this development.What's confirmed:UniQure intends to seek FDA approval for its Huntington's disease gene therapy.The FDA reversed its previous position regarding the gene therapy treatment.UniQure shares experienced a significant price increase following the news.The treatment in question is identified as AMT-130.Still unconfirmed:UniQure stock surged 81%